5:07 PM
 | 
Aug 26, 2013
 |  BC Extra  |  Clinical News

Rigel slides after dropping asthma compound

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) was down $0.49 (14%) to $3.14 on Monday after discontinuing development of R343, which was in Phase II testing to treat allergic asthma. The move came after twice-daily inhaled R343 missed the primary endpoint of improving forced expiratory volume in...

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >